ALCEDIAG presents EDITECH, a biomarker discovery service based on the company’s experience and expertise in RNA editing.

ALCEDIAG has developed EDITECH, a platform and methodology for discovering and validating biomarkers based on the study of RNA editing. ALCEDIAG uses EDITECH for its own developments, as well as proposing it as a service. EDITECH combines cutting-edge molecular biology and Artificial Intelligence to enable the development of tailor-made biomarkers, designed specifically to answer the clinical queries of the user. EDITECH makes it possible to discover new biomarkers in no more than a few months.

This platform can be used whenever the pathology targeted is related to RNA editing modifications. Such relations have been identified thus far for a large number of diseases including:

• Neuropsychiatric diseases: depression, bipolar disorder, schizophrenia, Alzheimer’s, suicidal behavior, etc.;
• Inflammatory & infectious diseases: SARS-CoV2, Systemic Lupus Erythematosus, Aicardi Gouttiere syndrome, systemic inflammation, etc.;
• Cancer: hepatocellular carcinoma, breast, lung, kidney, prostate, gastric cancer, metastatic melanoma, etc.;
• Metabolic diseases: Obesity, diabetes, cardiac dysfunction, ischemia, atherosclerosis, etc.

During a rapid process lasting no longer than a few months, ALCEDIAG performs a series of blood NGS analyses on a set of patients and controls, as well as a network analysis. The company can then confirm the results on a discovery cohort. ALCEDIAG adapts the process to its clients’ needs, to the pathology and to the clinical query being addressed.